Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
M
MLTX
vs
S&P 500
S&P 500
Over the past 12 months, MLTX has outperformed S&P 500, delivering a return of +20% compared to S&P 500's +11% growth.
Stocks Performance
MLTX vs S&P 500
Performance Gap
MLTX vs S&P 500
Performance By Year
MLTX vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
MoonLake Immunotherapeutics
Glance View
MoonLake Immunotherapeutics is a clinical-stage biotechnology company that develops medicines for inflammatory and autoimmune diseases. Its main drug candidate is sonelokimab, a lab-made antibody fragment designed to block a pathway involved in conditions such as psoriasis and hidradenitis suppurativa. The company is still focused on testing and advancing this drug rather than selling a broad portfolio of products. MoonLake does not make money from consumer sales or a large existing drug line. It is mainly funded through research partnerships, financing activities, and the future goal of commercializing a successful therapy after regulatory approval. In practice, its business is about creating a new treatment, proving it works and is safe, and then building a drug franchise around it. What makes MoonLake different is its focus on a specialized antibody format that is meant to reach hard-to-treat inflammatory targets with a smaller, more precise drug design. For investors, the key point is that this is a focused biotech company: its value depends heavily on the clinical and regulatory success of one lead medicine and the size of the patient markets it could eventually serve.